TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19843000

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (20 mg three times daily, increased to 40 mg and 80 mg tid)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (20 mg, 40 mg, and 80 mg tid)
Number of subjects: 35
Study: 16894098

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study: 14984383

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Aspirin (low-dose)
Number of subjects: 129
Study: 12539684

Group type: EXPERIMENTAL
Intervention: Millimeter wave treatment (7.1 mm, 43 GHz, 10 mW/cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Millimeter wave treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (soothing treatment)
Number of subjects: 30
Study: 9018645

Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started immediately after PGE2 placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started six hours after PGE2 placement
Number of subjects: 50
Study: 7887039

Group type: EXPERIMENTAL
Intervention: Reusable instruments
Number of subjects: 158

Group type: COMPARATOR
Intervention: Disposable instruments
Number of subjects: 158
Study: 2196372

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 18
Study: 87314

Group type: EXPERIMENTAL
Intervention: Diffuse brain stimulation (DBS) for 20 minutes before sleep onset
Number of subjects: 16
Study: 30303427

Group type: EXPERIMENTAL
Intervention: FS Grifols
Number of subjects: 224

Group type: COMPARATOR
Intervention: Surgicel®
Number of subjects: 224
Study: 31082818

Group type: EXPERIMENTAL
Intervention: Total contact cast and a skin substitute (human amniotic allograft)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Total contact cast and standard wound care
Number of subjects: 13
Study: 25599319

Group type: EXPERIMENTAL
Intervention: Platelet Gel Supernatant (PGS) plus supportive medical treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive medical treatment alone
Number of subjects: 80
Study: 26214609

Group type: EXPERIMENTAL
Intervention: Traditional Persian medical schemes and recommendations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 100
Study: 23007693

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic counseling
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 160
Study: 21303505

Group type: EXPERIMENTAL
Intervention: Loozit® group intervention
Number of subjects: 151
Study: 19342442

Group type: EXPERIMENTAL
Intervention: 500 microg/d folic acid (FA) for 8 weeks, then discontinued for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: No supplements (Control group)
Number of subjects: 27
Study: 16650363

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study: 17152306

Group type: EXPERIMENTAL
Intervention: Writing-to-learn (WTL) strategy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study: 11714895

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 5 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo 0 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faster infusion rates of morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (both doses)
Number of subjects: 0
Study: 9137028

Group type: EXPERIMENTAL
Intervention: 6-hour heparin flushing interval
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 8-hour heparin flushing interval
Number of subjects: 83

Group type: COMPARATOR
Intervention: 4-hour heparin flushing interval
Number of subjects: 83

Group type: COMPARATOR
Intervention: 22-gauge catheters
Number of subjects: 83

Group type: COMPARATOR
Intervention: 24-gauge catheters
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Age differences in catheter longevity
Number of subjects: 83
Study: 8181019

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACE-I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists or alternative RAAS blockers (renin inhibitors or angiotensin II receptor blocking agents)
Number of subjects: 0
Study: 2142116

Group type: EXPERIMENTAL
Intervention: Intramuscular etofenamate
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intramuscular diclofenac sodium
Number of subjects: 96
Study: 580214

Group type: EXPERIMENTAL
Intervention: tramadol (Tramal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dextropropoxyphene
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: commercial drug mixture (acetylsalicylic acid 200 mg; phenacetin 200 mg; codeine phosphor. 10 mg; caffeine anhydr. 50 mg; phenobarbital 25 mg)
Number of subjects: 60
Study: 31157983

Group type: EXPERIMENTAL
Intervention: CHANGE Asthma app
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 40
Study: 29380610

Group type: EXPERIMENTAL
Intervention: Ultrasound enamel preparation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional diamond bur preparation
Number of subjects: 60
Study: 26181254

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) alone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT) + SRS
Number of subjects: 88
Study: 23928630

Group type: EXPERIMENTAL
Intervention: Video accompanied by a written leaflet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Leaflet alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 90
Study: 21665136

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Psychosocial support therapy (PST) control
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 19
Study: 19803365

Group type: EXPERIMENTAL
Intervention: Cytoflavine (10 mL per 24 hours, for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antituberculosis therapy (placebo control)
Number of subjects: 0
Study: 16959692

Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (nonobese females)
Number of subjects: 27
Study: 14762779

Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 11315893

Group type: EXPERIMENTAL
Intervention: Topical GTN (10 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical saline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical ISDN (10 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical GTN
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical ISDN
Number of subjects: 80
Study: 9160362

Group type: EXPERIMENTAL
Intervention: Pulsatile pump flow
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpulsatile pump flow
Number of subjects: 0
Study: 8214791

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etching
Number of subjects: 600

Group type: COMPARATOR
Intervention: 2% phosphoric acid etching
Number of subjects: 600
Study: 3568581

Group type: EXPERIMENTAL
Intervention: Beta-blockade (2 X 80 mg oral propranolol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29735237

Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity (≥150 minutes/week)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity physical activity
Number of subjects: 147
Study: 27108821

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2.5g intravenous, 5min before tourniquet release)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 62
Study: 24015935

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (350 mg Mg d(‐1), 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (500 mg maltodextrin d(‐1), 4 weeks)
Number of subjects: 25
Study: 23541623

Group type: EXPERIMENTAL
Intervention: 5 μg of EV71 antigen with 150 μg of adjuvant (Group A05)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 μg of EV71 antigen with 300 μg of adjuvant (Group B10)
Number of subjects: 60
Study: 20734365

Group type: EXPERIMENTAL
Intervention: quetiapine XR (50-300 mg/day)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 776

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 776
Study: 18439112

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15992232

Group type: EXPERIMENTAL
Intervention: Measurement of ear temperature bilaterally using an infrared tympanic thermometer (ITT)
Number of subjects: 132
Study: 12742289

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (CAs)
Number of subjects: 3327

Group type: EXPERIMENTAL
Intervention: Non-dihydropyridines
Number of subjects: 3327
Study: 10370667

Group type: EXPERIMENTAL
Intervention: 6MU IFN-alpha 2a t.i.w. for 3 months followed by 3MU t.i.w. for another 3 months (group A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 3MU IFN-alpha 2a t.i.w. for 6 months (group B)
Number of subjects: 63
Study: 8668894

Group type: EXPERIMENTAL
Intervention: High-dose i.v. methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral steroids (1 mg per kilogram of body weight per day)
Number of subjects: 0
Study: 2067345

Group type: EXPERIMENTAL
Intervention: Reaferon (alpha 2‐interferon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prodigiosan plus ibuprofen
Number of subjects: 0
Study: 6409456

Group type: EXPERIMENTAL
Intervention: Long-acting met-enkephalin analogue DAMME
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cholinergic antagonist, pirenzepine
Number of subjects: 6
Study: 31347010

Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Relaxation training (control)
Number of subjects: 152
Study: 29985775

Group type: EXPERIMENTAL
Intervention: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (551 mg EPA and 551 mg DHA) twice daily (FO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Protein-based placebo (P)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (FO)
Number of subjects: 20
Study: 26370224

Group type: EXPERIMENTAL
Intervention: Bilayer technique protected with petroleum jelly (PJ)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Conventional GIC insertion protected with nano‐filled particles coating (NPC)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional GIC insertion protected with petroleum jelly (PJ)
Number of subjects: 208
Study: 24354307

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22560253

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling by nurse practitioner (NP) for three years
Number of subjects: 457

Group type: COMPARATOR
Intervention: Usual care by general practitioner (GP) with one consultation
Number of subjects: 457
Study: 19958042

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.25 mg twice daily for 6 weeks, then 0.5 mg twice daily for 6 weeks)
Number of subjects: 14
Study: 17293206

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP) at 50 beats/min greater than the mean nocturnal heart rate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP) at 20 beats/min greater than the mean nocturnal heart rate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP) at 10 beats/min greater than the mean nocturnal heart rate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control studies
Number of subjects: 14
Study: 15385341

Group type: EXPERIMENTAL
Intervention: Esmolol plus enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 microg x kg(‐1) x min(‐1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline solution as placebo (control)
Number of subjects: 42
Study: 12506821

Group type: EXPERIMENTAL
Intervention: Puréed food texture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Minced food texture
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Soft food texture
Number of subjects: 3
Study: 9561866

Group type: EXPERIMENTAL
Intervention: Procaine penicillin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sulbactam-ampicillin
Number of subjects: 42
Study: 7855784

Group type: EXPERIMENTAL
Intervention: High-purity factor VIII concentrate (HP-F VIII)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ultra-pure factor VIII product (UP-F VIII)
Number of subjects: 36
Study: 2670395

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.5 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 3 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion at 0.5 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion at 3 microgram/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 6 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion at 6 microgram/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic glucose clamp
Number of subjects: 0
Study: 824068

Group type: EXPERIMENTAL
Intervention: Inhaled BRL 10833, dosage: 40 mg
Number of subjects: 10
Study: 31286906

Group type: EXPERIMENTAL
Intervention: Brief structured intervention (n = 107)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Usual care (n = 117)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 261
Study: 28637708

Group type: EXPERIMENTAL
Intervention: Hypohydration (HYP) - induced by 2.5% body mass loss
Number of subjects: 7

Group type: COMPARATOR
Intervention: Euhydration (EU) - replaced sweat loss
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hypohydration (HYP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Euhydration (EU)
Number of subjects: 7
Study: 25837247

Group type: EXPERIMENTAL
Intervention: VbX warm‐up (VbX‐WU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neural activation warm‐up (Neu‐WU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynamic warm‐up (Dyn‐WU)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (No VbX)
Number of subjects: 12
Study: 23439063

Group type: EXPERIMENTAL
Intervention: PC‐DC injections
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 13
Study: 20816037

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 44
Study: 17869451

Group type: EXPERIMENTAL
Intervention: CT‐RT(90‐01)
Number of subjects: 302

Group type: COMPARATOR
Intervention: CT‐RT(SC(C/F))
Number of subjects: 302

Group type: COMPARATOR
Intervention: CT‐RT(SC(WC))
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: C/F chemotherapy, cisplatin dose >or=200 mg/m(2), Stage I‐II disease, negative pelvic lymph nodes
Number of subjects: 302
Study: 17112689

Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional neonatal care
Number of subjects: 25
Study: 15319332

Group type: EXPERIMENTAL
Intervention: 1 mg of [(14)C]tesaglitazar (intravenous)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1 mg of nonlabeled tesaglitazar (oral)
Number of subjects: 8
Study: 11341460

Group type: EXPERIMENTAL
Intervention: Betula 30c
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9481614

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 14
Study: 7940139

Group type: EXPERIMENTAL
Intervention: Pulsatile ocular blood flow (POBF) measurement in NTG patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 2908715

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study: 31267162

Group type: EXPERIMENTAL
Intervention: Postfracture notification program
Number of subjects: 18541

Group type: COMPARATOR
Intervention: Control group (without a MOF; N = 92,705)
Number of subjects: 18541
Study: 28544892

Group type: EXPERIMENTAL
Intervention: Dynamic expression of emotions
Number of subjects: 97

Group type: COMPARATOR
Intervention: Static images of realistic human faces
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Mood-induction (positive or negative)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Trial-to-trial bias estimations
Number of subjects: 97
Study: 26152126

Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet supplemented with placebo (LFHCC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long chain n-3 polyunsaturated fatty acids (LFHCC n-3)
Number of subjects: 24
Study: 23117050

Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 86
Study: 21983400

Group type: EXPERIMENTAL
Intervention: Visit from Smiling Hospital artists
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no visit from artists)
Number of subjects: 24
Study: 19230168

Group type: EXPERIMENTAL
Intervention: Strategies used by clinicians to facilitate decision making during randomization.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clinicians' motivation for randomizing patients.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Regular meetings with the study group.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Patients' attitudes towards randomization.
Number of subjects: 9
Study: 16585808

Group type: EXPERIMENTAL
Intervention: Reminder postcard
Number of subjects: 49605

Group type: EXPERIMENTAL
Intervention: Thank you postcard
Number of subjects: 49605

Group type: COMPARATOR
Intervention: Control group (no postcard)
Number of subjects: 49605
Study: 12566871

Group type: EXPERIMENTAL
Intervention: Clonidine 0.125%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1.0%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10866352

Group type: EXPERIMENTAL
Intervention: Controlled procedure with constant reinforcer ratio
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Uncontrolled procedure with variable reinforcer ratio
Number of subjects: 8
Study: 8627032

Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cocultivation with macrophages
Number of subjects: 38
Study: 1419616

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 4044343

Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiation (4000 rad) plus intraperitoneal radioactive chromic phosphate (10-20 millicuries)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (18 patients who did not receive chromic phosphate)
Number of subjects: 53
Study: 31167870

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) as an open label add-on for primary CBD non-responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study: 30283981

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27549590

Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity (SPA) - 2 sessions per week for 20 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Progressively Autonomous Physical Activity (PAPA) - 10 weeks of SPA followed by 10 weeks with one supervised session replaced by habit formation strategy
Number of subjects: 56
Study: 24102348

Group type: EXPERIMENTAL
Intervention: Oral liarozole 75 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral liarozole 150 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral liarozole (both doses)
Number of subjects: 64
Study: 22609619

Group type: EXPERIMENTAL
Intervention: Acute dose of levodopa
Number of subjects: 55
Study: 20417063

Group type: EXPERIMENTAL
Intervention: 2mg trihexyphenidyl
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18078614

Group type: EXPERIMENTAL
Intervention: Combination DMARD therapy (sulfasalazine, methotrexate, hydroxychloroquine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single DMARD therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline IL-1beta levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1beta levels at 0 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1beta levels
Number of subjects: 0
Study: 16107874

Group type: EXPERIMENTAL
Intervention: Activity Restriction (AR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No Activity Restriction (No AR)
Number of subjects: 73